Expects topline results from the SAD portion of a first-in-human study with pan-coronavirus and pan-norovirus oral protease inhibitor CDI-988.

Expects to report topline results from Phase 2a human challenge study with broad-spectrum oral PB2 inhibitor CC-42344 for pandemic and seasonal influenza A and to prepare an IND application to conduct a late-stage clinical study in the U.S. in the second half of 2024.

Preparations are underway to initiate a Phase 1 study in healthy volunteers with inhaled CC-42344 as a potential prophylactic and therapeutic for influenza A in the second half of this year.

Anticipates significant milestones this year and expects cash will be sufficient to fund operating activities beyond the next twelve months.